Neuroblastoma, derived from neural crest progenitor cells, is the most common extracranial solid tumor of childhood. Astrocyte elevated gene-1 (AEG-1) is a primary mediator of tumor progression and metastasis in several human cancers. In this study, we investigated the potential contribution of AEG-1 in human neuroblastoma pathogenesis. AEG-1 expression was significantly elevated in neuroblastoma patient-derived samples and neuroblastoma cell lines as compared with normal peripheral nerve tissues, normal astrocytes and immortalized melanocytes. Knockdown of AEG-1 by small interfering RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells. Conversely, over-expression of AEG-1 enhanced proliferation and expression of the transformed state in less aggressive neuroblastoma cells through activation of the phosphatidylinositol 3-kinase-Akt-signaling pathway and stabilization of MYCN. These provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of neuroblastoma and could represent a potential target for therapeutic intervention.
Introduction
Neuroblastoma, a tumor of peripheral neural crest origin, is the most common extracranial solid tumor in infancy and childhood and accounts for 7-10% of pediatric malignancies and approximately 15% of pediatric cancer-related deaths (Brodeur, 2003; Schwab et al., 2003) . The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying according to age at diagnosis, extent of disease and tumor biology (Maris et al., 2007) . Roughly half of patients are currently classified as high-risk disease characterized by unresectable primary lesions and multiple metastases, with overall survival rates of o40% in spite of the intensive multimodal therapy (Brodeur, 2003; Maris et al., 2007) . Considering these statistics, it is important to investigate and define the molecular mechanism(s) underlying neuroblastoma development and progression, to identify novel prognostic markers and potential therapeutic targets for this disease, and to ultimately develop more effective and rationally based therapeutic strategies.
Astrocyte elevated gene-1 (AEG-1) was originally isolated by our group as a human immunodeficiency virus type 1-and tumor necrosis factor a-inducible gene in primary human fetal astrocytes (PHFA) (Su et al., 2002 (Su et al., , 2003 Kang et al., 2005) . Intriguingly, the expression of AEG-1 is significantly elevated in subsets of breast cancers, malignant gliomas, prostate cancers and melanoma cell lines (Kang et al., 2005) . Overexpression of AEG-1 augments the anchorage-independent growth, migration and invasion properties of HeLa and human glioma cell lines by activating the nuclear factor (NF)-kB pathway (Emdad et al., , 2007 Sarkar et al., 2008) . Conversely, AEG-1 small interfering RNA (siRNA) significantly inhibits migration and invasion of human glioma and prostate cancer cell lines and in vivo lung metastasis of breast cancer cells (Brown and Ruoslahti, 2004; Emdad et al., 2007; Kikuno et al., 2007) . Interestingly, AEG-1 itself is a downstream target of oncogenic Ras and plays an important role in mediating the growth-promoting effects of Ras (Lee et al., 2006) . AEG-1 also activates cell survival pathways through phosphatidylinositol 3-kinase (PI3K)-Akt signaling (Lee et al., 2008b) . The mouse AEG-1 gene was cloned by in vivo phage screening as Metadherin, a gene mediating metastasis of breast cancer cells to the lung (Brown and Ruoslahti, 2004) . Other recent studies also reported that AEG-1 is a novel prognostic marker for breast cancer progression and its expression inversely correlates with overall patient survival (Li et al., 2008; Hu et al., 2009 ). These observations indicate that AEG-1 may play a fundamental and global role in cancer development and progression.
In this study, we focused on elucidating the role of AEG-1 in the pathogenesis of neuroblastoma. We show that AEG-1 is overexpressed in neuroblastoma patient samples and cell lines compared with normal peripheral nerve tissues, PHFA and immortalized normal melanocyte cells (FM516-SV). We also found that overexpression of AEG-1 converts non-tumorigenic neuroblastoma cells to highly proliferative and aggressive tumor cells, and conversely that knockdown of AEG-1 can block the tumorigenic properties of highly aggressive neuroblastoma cells. Our experiments also provide insights into the molecular and biochemical mechanisms by which AEG-1 augments neuroblastoma progression.
Results
Elevated expression of AEG-1 in neuroblastoma patient tissues and neuroblastoma cell lines To assess a potential role of AEG-1 in neuroblastoma, we first examined the expression of AEG-1 using a tissue microarray containing 10 human neuroblastoma patient-derived tissues and two human normal peripheral nerve tissues. Whereas no AEG-1 immunostaining was observed in normal nerve tissues, significant AEG-1 staining was detected in neuroblastoma patient-derived samples (Figures 1a-d ). Significant positive staining of AEG-1 was observed predominantly in the perinuclear region of six neuroblastoma samples among 10 cases, and four samples had no AEG-1 expression (Figures 1c  and d ; and data not shown). These results were also confirmed in neuroblastoma cell lines by western blot analysis. As shown in Figure 1e , all neuroblastoma cell lines except SH-EP, which is a less aggressive neuroblastoma cell line, had much higher expression of AEG-1 compared with normal cells, PHFA and FM516-SV. These results indicate that AEG-1 expression is notably increased in the neuroblastoma.
Knockdown of AEG-1 in the BE(2)-C cell line suppresses transformation-associated properties in vitro and tumorigenesis in vivo To further understand AEG-1 function in neuroblastoma, we established AEG-1 knockdown cell lines by stable transfection with a plasmid expressing AEG-1 siRNA or negative control siRNA in BE(2)-C cells, a highly aggressive and tumorigenic neuroblastoma cell line with high levels of AEG-1 expression. AEG-1 knockdown in the clones was confirmed by western blot analysis (Figure 1f) . To investigate the effects of AEG-1 knockdown on neuroblastoma growth in vivo, we established BE(2)-C-negative control siRNA (NCsi) or BE(2)-C-AEG-1 siRNA (AEG1si) xenografts in athymic nude mice. Noticeably, as shown in Figure 1g , mice injected with the AEG1si-3 or the AEG1si-13 clone did not establish any visible tumors, whereas control mice bearing NCsi xenografts generated large and very aggressive tumors. Tumor weights were assessed 21 days after injection. As expected the size of AEG1si xenografts were too small to measure tumor volumes at earlier time points after injection, and tumor weights of mice injected with AEG1si, accordingly, were considerably lower than that of NCsi mice (Figure 1h ). In parallel, we also examined the effect of AEG-1 knockdown in BE(2)-C cells in vitro using the NCsi and AEG1si clones. Analysis of cell proliferation by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assays showed that both AEG1si-3 and AEG1si-13 clones had a lower growth rate compared with the NCsi control clone (Figure 2a) . These results were confirmed by colony formation assays in monolayer culture. As shown in Figure 2c , both colony number and colony size of AEG1si clones were smaller than those of NCsi. The knockdown of AEG-1 also affected cell proliferation under serum starvation (0.15% fetal bovine serum (FBS)) conditions, indicating that AEG-1 was capable of inducing serum-independent growth of neuroblastoma cells. Whereas the growth rate of the NCsi clone steadily increased in a time-dependent manner, the growth of AEG1si-3 and AEG1si-13 clones was stagnant under serum starvation conditions ( Figure 2b ). Both AEG1si clones also showed reduced anchorage-independent growth in soft agar (Figure 2d ). In Matrigel invasion assays, AEG1si-3 and AEG1si-13 clones had significantly reduced invasive ability compared with the NCsi clone ( Figure 2e ). Altogether, these results indicate that AEG-1 plays a central role in expression of the transformed state and the pathogenesis of neuroblastoma.
Overexpression of AEG-1 in Tet21N cells enhances expression of the transformed state
To elucidate the consequence of AEG-1 overexpression in neuroblastoma, we established AEG-1-overexpressing cell lines in Tet21N, a subclone of SH-EP cells expressing MYCN, a key oncogene in neuroblastoma, driven by a tetracycline-regulated promoter (Tet-off system) (Fotsis et al., 1999; Sagulenko et al., 2008) . In Tet21N cells MCYN is expressed in the absence of doxycycline (Dox), whereas expression is shut off when cells are grown in this antibiotic. A Tet21N cell line stably transfected with pcDNA3.1 was used as a control cell line (PC). Tet21N-AEG-1-7 (AEG-1-7) and Tet21N-AEG-1-8 (AEG-1-8) clones overexpressed AEG-1, although the PC clone had little expression of AEG-1 as found earlier in SH-EP cells (Figure 3a) . Regulation of MYCN expression by Dox was also confirmed by western blot analysis, and the expression level of MYCN, interestingly, was higher in AEG-1-7 and AEG-1-8 clones compared with the PC control clone (Figure 3a) , indicating a possible mechanism by which AEG-1 plays a role in neuroblastoma progression. Using these stable cell lines, we examined the effect of AEG-1 with MYCN in Tet21N cell proliferation. As shown in Figures 3b and c, cell proliferation of the AEG-1-7 and AEG-1-8 cell lines in normal growth conditions as well as in serum starvation conditions was greater than that of the PC control cell line in the presence of Dox, suggesting that AEG-1 itself induces cell proliferation of Tet21N cells. However, with withdrawal the of Dox, induction of MYCN further activated AEG-1-mediated cell growth under normal growth medium and serum starvation conditions, even though MYCN also increased cell growth rate in the PC clone (Figures 3b and c) . These results suggest that AEG-1 and MYCN can cooperate in regulating neuroblastoma cell proliferation. These effects were confirmed in colony formation assays in monolayer culture. As shown in Figure 3d , colony number was increased by MYCN or AEG-1 overexpression. Interestingly, when AEG-1 and MYCN were overexpressed together, colony number was similar with that of the Representative immunostaining of AEG-1 in normal peripheral nerve tissues (a and b) and neuroblastomas (c and d) (magnification, Â 400). (e) Expression of AEG-1 was observed in the indicated cell lines. Western blotting was carried out with total cell lysates using an AEG-1 antibody or an actin antibody (loading control). (f) The NCsi (control siRNA), AEG1si-3 and AEG1si-13 cell lines were established in BE(2)-C cells and the knockdown of AEG-1 was confirmed by western blot analysis. (g) Tumor volumes of the subcutaneous xenografts in athymic nude mice were measured at the indicated time points after injection with each indicated clone. (h) Tumor weights were measured after killing the mice at 21 days after injection. The data in graphs represent mean±s.e.m. with five animals in each group (*Po0.05 vs NCsi). AEG1si-3, BE(2)-C cells stably expressing AEG-1 siRNA; NCsi, BE(2)-C cells stably expressing negative control siRNA; PHFA, primary human fetal astrocytes; siRNA, small interfering RNA.
AEG-1 alone, but colony size was significantly larger (Figure 3d ), indicating the cooperation of AEG-1 and MYCN in controlling neuroblastoma cell proliferation. In anchorage-independent growth assays, AEG-1 or MYCN overexpression alone could not induce formation of soft agar colony in Tet21N cells (Figure 3e ). However, only when both AEG-1 and MYCN were overexpressed together did the Tet21N cells form colonies in soft agar even though agar-cloning efficiency was low (Figure 3e ), suggesting that cooperation of AEG-1 with MYCN makes neuroblastoma cells phenotypically more transformed. In invasion assays, MYCN and AEG-1 induced significantly higher invasion in Tet21N cells, but no cooperative effect of MYCN and AEG-1 was evident (Figure 3f ). These results suggest that AEG-1 may play a crucial role in the pathogenesis of neuroblastoma by cooperating with MYCN in augmenting specific transformation-associated properties in neuroblastoma cells.
Role of the PI3K-Akt-signaling pathway and MYCN in AEG-1-mediated neuroblastoma progression Recent studies suggest that the PI3K-Akt-signaling pathway is involved in tumor progression and poor outcome of neuroblastoma and contributes to the stabilization of the MYCN protein (Yaari et al., 2005; Chesler et al., 2006; Opel et al., 2007) . Our earlier investigations documented that AEG-1 activates cell survival through the PI3K-Akt-signaling pathway (Lee et al., 2008b) . Additionally, as shown in Figure 3a , MYCN expression was higher in AEG-1-7 Figure 2 Knockdown of astrocyte elevated gene-1 (AEG-1) inhibits cell proliferation and survival, anchorage-independent growth and invasion of BE (2) and AEG-1-8 clones compared with the PC clone. These results suggested that AEG-1 might induce stabilization of MYCN protein by activating the PI3K-Akt-signaling pathway. This hypothesis was initially examined by western blot analysis in NCsi and AEG1si-3 clones and PC and AEG-1-8 clones. As evident in Figure 4a , knockdown of AEG-1 reduced MYCN expression, and phosphorylation of Akt and glycogen synthase kinase (GSK)3b in BE(2)-C cells. Conversely, AEG-1 overexpression increased MYCN expression as well as phosphorylation of Akt and GSK3b in Tet21N cells (Figure 4b ). In addition, treatment with LY294002 inhibited AEG-1-induced phosphorylation of Akt and GSK3b, and MYCN expression (Figure 4b ). These results indicate that AEG-1 activates the PI3K-Akt-signaling pathway resulting in induction of MYCN protein in neuroblastoma. To further examine if the PI3K-Akt-signaling pathway is crucial in AEG-1-mediated neuroblastoma cell proliferation and invasion, LY294002 and Wortmannin, pharmacological inhibitors of PI3K were employed. Both LY294002 and Wortmannin could not block MYCN-mediated cell proliferation, colony formation and invasion ( Figure 5 ). However, both inhibitors significantly inhibited cell proliferation of AEG-1-8 cell line in normal growth medium (15% FBS) as well as in serum-starvation (0.15% FBS) conditions (Figures 5a  and b) . In colony formation assays, both inhibitors 
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profoundly decreased colony number and the size of AEG-1-8 colonies (Figure 5c ). Matrigel invasion of AEG-1-8 clones was also significantly inhibited by both PI3K inhibitors (Figure 5d ). These results indicate that activation of the PI3K-Akt pathway induces MYCN expression and plays an important role in mediating AEG-1-induced cell proliferation, colony formation and Matrigel invasion in the Tet21N neuroblastoma cell line.
Discussion
Effective treatment of high-risk neuroblastoma remains a formidable challenge in pediatric oncology. In this context, defining the molecular and biochemical basis of neuroblastoma development and progression provides an entry point for generating future effective therapies for this disease. In this study, we provide evidence that AEG-1 may directly contribute to the pathogenesis of neuroblastoma. Whereas AEG-1 expression is low or undetectable in normal human peripheral nerve tissues, PHFA and immortalized melanocytes, its expression is significantly increased in a high percentage (6 of 10) of neuroblastoma patient samples and in neuroblastoma cell lines. In addition, knockdown of AEG-1 using siRNA results in inhibition of tumor formation in vivo in nude mice. Its knockdown also inhibited cell proliferation, colony formation, anchorage-independent growth and invasion in in vitro assays. Conversely, AEG-1 overexpression enhanced cell proliferation, colony formation, anchorage-independent growth and invasion, which are consistent measures of cell transformation and malignant potential. These results indicate that AEG-1 plays an important role in tumorigenesis of neuroblastoma. Furthermore, these observations also indicate that it will be revealing to check AEG-1 expression in a large number of archival neuroblastoma patient samples to determine if AEG-1 could potentially serve as a diagnostic or prognostic marker for neuroblastoma. Amplification of MYCN is frequently detected in neuroblastoma as a prognostic indicator of poor patient outcome, and is used for making therapeutic decisions (Brodeur et al., 1984; Seeger et al., 1985; Brodeur, 2003; Schwab et al., 2003; Maris et al., 2007) . PI3K-Akt governs many downstream signaling pathways involved in protein synthesis, glucose metabolism, cell proliferation and survival, and angiogenesis, and alterations of these pathways are frequent occurrences in cancers (Vivanco and Sawyers, 2002; Hamada et al., 2005; Yuan and Cantley, 2008) . Recent reports indicate that activation of the PI3K-Akt-signaling pathway is involved in neuroblastoma progression, and its activation also predicts poor prognosis in primary neuroblastoma (Yaari et al., 2005; Chesler et al., 2006; Ishola et al., 2007; Opel et al., 2007; Kang et al., 2008) . In addition, PI3K-Akt induces stabilization of MYCN protein (Yaari et al., 2005; Chesler et al., 2006) . Our earlier report documented that AEG-1 activates cell survival through activation of the PI3K-Akt-signaling pathway (Lee et al., 2008b) . In this study, we also found that AEG-1 could induce MYCN expression. Interestingly, AEG-1 did not activate MYCN expression in SH-EP cells (data not shown) and Tet21N cells treated with Dox in which MYCN could not be detected. However, when MYCN was expressed in Tet21N cells, AEG-1 elevated MYCN protein levels, and AEG-1 knockdown in BE(2)-C cells reduced MYCN protein. We also found that AEG-1 expression did not increase MYCN mRNA (data not shown). Additionally, we showed that AEG-1 activates the PI3K-Akt-signaling pathway causing inactivation of GSK3b, which is known to induce cMyc and MYCN stabilization (Sears, 2004; Yeh et al., 2004; Yaari et al., 2005; Chesler et al., 2006) . In total, these results indicate that AEG-1 can induce stabilization of MYCN protein by activating the PI3K-Aktsignaling pathway and this process may be an important mechanism by which AEG-1 contributes to the pathogenesis of neuroblastoma ( Figure 6 ).
We earlier reported that oncogenic Ras induces AEG-1 expression through the PI3K-Akt-signaling pathway by increasing c-Myc binding to the E-box elements of the AEG-1 promoter (Lee et al., 2006) (Figure 6 ). MYCN is an established transcription factor, which can bind to the E-box element as a MYCN-Max heterodimer inducing transcriptional activation of target genes or as a heterodimer with Mnt, Mad or other negative cofactors causing transcriptional repression (Sakamuro and Prendergast, 1999; Grandori et al., 2000) . These reports suggest that MYCN may bind to the E-box element on the AEG-1 promoter causing induction of AEG-1 expression, possibly inducing a positive feedback loop between MYCN and AEG-1 through the PI3K-Akt-signaling pathways. This possibility is currently under investigation, and we already have a clue that MYCN binds to the E-box elements of the AEG-1 promoter by using chromatin immunoprecipitation analysis, even though its binding is less efficient than with c-Myc (data not shown). Further investigations are necessary to mechanistically define the multiple roles of AEG-1 in neuroblastoma pathogenesis.
As summarized in Figure 6 , as a downstream target gene of the Ras-PI3K-Akt pathway AEG-1 plays crucial roles in regulating the transformed state in multiple types of cancers, including melanoma, breast cancer, prostate cancer, and brain tumors including malignant gliomas through activating various signaling molecules such as PI3K-Akt, NF-kB, AP-1 and ERK (Brown and Ruoslahti, 2004; Kang et al., 2005; Emdad et al., 2006 Emdad et al., , 2007 Lee et al., 2006 Lee et al., , 2008b Kikuno et al., 2007; Li et al., 2008; Sarkar et al., 2008) , and we now show that AEG-1 functions as a key regulator of the PI3K-Akt-signaling pathway and MYCN expression in neuroblastoma. Moreover, a recent study also indicates a pivotal role of AEG-1 in the pathogenesis of hepatocellular carcinoma (Yoo et al., 2009) . These findings suggest an expanded global role for AEG-1 in tumor progression. The present observations suggest that AEG-1 might serve as a prognostic or diagnostic marker for neuroblastoma. Further studies are warranted and will lead to a more precise understanding of the relationship between AEG-1 and MYCN, PI3K-Akt, and other signaling pathways that are crucial in neuroblastoma development and progression. Developing genetic and pharmacological approaches to inhibit AEG-1 expression or its downstream-regulated target genes/pathways could serve as a means of intervening in the pathogenesis of neuroblastoma in children, as well as in developing therapies for other cancers.
Materials and methods

Tissue microarray and immunohistochemistry
Tissue microarray (MC803) containing 10 neuroblastoma patient tissues and two normal peripheral nerve tissues in duplicate was purchased from US Biomax Inc. (Rockville, MD, USA). The slide was deparaffinized and permeabilized Role of AEG-1 in neuroblastoma S-G Lee et al with 0.1% TritonX-100 in phosphate buffered saline for 30 min. The slide was then blocked for 1 h at room temperature with 2% goat serum and 1% bovine serum albumin in phosphate buffered saline and incubated with anti-AEG-1 antibody (Invitrogen, Camarillo, CA, USA) overnight at 4 1C. The signal was developed by avidin-biotin-peroxidase complexes with DAB substrate solution (Vector laboratories, Burlingame, CA, USA).
Plasmids and reagents
The pcDNA3.1(Hyg)-AEG-1-HA was described earlier (Kang et al., 2005) . The pcDNA3.1 (Zeo)-AEG-1-HA was constructed by inserting the BamHI/XhoI fragment of the pcDNA3.1(Hyg)-AEG-1-HA into BamHI/XhoI sites of the pcDNA3.1/Zeo plasmid (Invitrogen). The AEG-1 siRNA and negative control siRNA plasmids containing a Hygromycin resistant gene as a selection marker were purchased form SA Biosciences (Frederick, MD, USA). Dox, LY294002 and Wortmannin were purchased from Calbiochem (San Diego, CA, USA). Hygromycin and Zeocin were purchased from Invitrogen.
Cell lines
The PHFA and FM516-SV cells were described earlier (Lee et al., 2008b) . The SH-EP, IMR-32, BE(2)-C, SK-N-SH and NGP cells were cultured as described (Van Maerken et al., 2006 (Fotsis et al., 1999; Sagulenko et al., 2008) . The Tet21N-PC, Tet21N-AEG-1, BE(2)-C-NCsi and BE(2)-C-AEG-1si cell lines were generated by transfection with pcDNA3.1/Zeo, pcDNA3.1(Zeo)-AEG-1-HA, negative control siRNA and AEG-1 siRNA plasmid, respectively, and selection with Zeocin or Hygromycin.
Western blotting analysis
Whole cell lysates were prepared and western blotting analysis was carried out as described earlier (Lee et al., 2008b) . The antibodies for HA, AEG-1, actin, Akt and phospho-Akt (S473) were described earlier (Lee et al., 2006 (Lee et al., , 2008a Sarkar et al., 2008) . The antibody for MYCN was purchased from Cell Signaling Technology Inc. (Danvers, MA, USA).
Cell proliferation assays
Cell proliferation was determined by MTT assay and colony formation assay as described (Lee et al., 2006 (Lee et al., , 2008b . Briefly, for MTT assay, cells were seeded in 96-well plates (2 Â 10 3 cells/well), and 1-day after seeding the cells were treated with normal medium containing 15% FBS or serum starvation condition medium containing 0.15% FBS with or without the indicated pharmacological inhibitors. For colony formation assays, cells were seeded in 6-cm plates (200 cells/ plate), and then the cells were treated with the indicated pharmacological inhibitors. Colonies of >50 cells were scored after 2 weeks.
Invasion assays and anchorage-independent growth assays Invasive ability and anchorage-independent growth ability of the cells were determined as described earlier (Sarkar et al., 2008) . Invasion was measured by seeding 5 Â 10 4 cells in a modified Boyden chamber with a polycarbonate nucleopore membrane (BD Bioscience, Bedford, MA, USA) according to the manufacture's instruction. Anchorage-independent growth assays were carried out by seeding 1 Â 10 5 cells in 0.4% Noble agar on a 0.8% agar base layer both of which contain growth medium. Colonies were counted 2 weeks after seeding.
Xenograft studies in athymic nude mice Subcutaneous xenografts were established in the flanks of athymic nude mice using 1 Â 10 6 cells of each cell line. Tumor volumes were measured weekly with a caliper and calculated using the formula p/6 Â larger diameter Â (smaller diameter) 2 . Tumor weights were measured after killing the mice. All experiments were performed with five mice in each group.
Statistical analysis
All the experiments were performed at least three times. The results are expressed as mean ± standard deviation (s.d.) or standard error of mean (s.e.m.). Statistical comparisons were made using an unpaired two-tailed Student's t-test. A Po0.05 was considered as significant.
Abbreviations
AEG-1, astrocyte elevated gene-1; AEG-1-7 and AEG-1-8, Tet21N clone 7 and 8 stably expressing AEG-1; AEG1si, BE(2)-C cells stably expressing AEG-1 siRNA; Dox, doxycycline; FBS, fetal bovine serum; GSK, glycogen synthase kinase; LY, LY294002; NCsi, BE(2)-C cells stably expressing negative control siRNA; NF-kB, nuclear factor-kB; PC, Tet21N cells stably transfected with pcDNA3.1/Zeo; PHFA, primary human fetal astrocytes; PI3K, phosphatidylinositol 3-kinase; s.d., standard deviation; s.e.m., standard error of mean; WT, Wortmannin.
